Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics

Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics

Over the past two decades, the biopharmaceutical industry has seen unprecedented expansion and innovation in concert with significant technological advancements. While the industry has experienced marked growth, the regulatory system in the United States still operates at a capacity much lower than...

Full description

Bibliographic Details
Main Authors: Ryan D. Rykhus, Zachary V. Shepard, Alix Young, Hadley Frisby, Kailee A. Calder, Collin M. Coon, Justin A. Falk, Sydney R. McAndrews, Aspen Turner, Christina Chang, Johanna Michelsohn, Raegan Petch, Sarah M. Dieker, Benjamin H. Markworth, Kevin Alamo-Perez, Aaron J. Hosack, Jacob M. Berg, Christian Schmidt, Joachim Storsberg, Mark A. Brown
Format: Article
Language:English
Published: MDPI AG 2017-12-01
Series:Diseases
Subjects:
FDA
commercial drug approval
privatization
windfall tax
Online Access:https://www.mdpi.com/2079-9721/6/1/2

Internet

https://www.mdpi.com/2079-9721/6/1/2

Similar Items